

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**EVERGRANDE HEALTH
INDUSTRY GROUP**

EVERGRANDE HEALTH INDUSTRY GROUP LIMITED

恒大健康產業集團有限公司

(a company incorporated in Hong Kong with limited liability)

(Stock code: 708)

PROFIT WARNING

This announcement is made by Evergrande Health Industry Group Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the information currently available to the management, the Group is expected to record a net loss for the twelve months ended 31 December 2019 (“**Year of 2019**”) of approximately RMB4.9 billion, whereas the net loss of the Group for the twelve months ended 31 December 2018 was approximately RMB1.428 billion.

The Group expects that the net loss recorded in the Year of 2019 is primarily attributable to the development of the new energy vehicle business, which is in its investment stage and resulted in an increase in fees related to the purchase of fixed assets and equipments, research and development and interest expenses. The Company itself and the new energy vehicle business of the Group are expected to record a net loss for the Year of 2019 of approximately RMB2 billion and RMB3.2 billion, respectively. The health management segment of the Group recorded a net profit of approximately RMB300 million during the same period.

The information contained in this announcement is only a preliminary assessment by the management of the Company based on the financial information currently available to the management, and is not based on any figures or information which has been audited or reviewed by the Company’s auditor or the audit committee of the Board. Shareholders and potential investors are advised to read carefully the annual results announcement of the Company for the Year of 2019, which is expected to be published by the end of March 2020.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Evergrande Health Industry Group Limited
Shi Shouming
Chairman

Hong Kong, 22 March 2020

As at the date of this announcement, the executive directors of the Company are Mr. SHI Shouming, Mr. PENG Jianjun and Mr. QIN Liyong; and the independent non-executive directors of the Company are Mr. CHAU Shing Yim David, Mr. GUO Jianwen and Mr. XIE Wu.